Novel <sup>18</sup>F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of <sup>18</sup>F-LY2459989 in Nonhuman Primates.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28747521.
- Also identified by DOI 10.2967/jnumed.117.195586 and PMC identifier 5750518.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several <sup>11</sup>C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evaluation of <sup>18</sup>F-LY2459989 as the first <sup>18</sup>F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with <sup>11</sup>C-LY2459989. <b>Methods:</b> The novel radioligand <sup>18</sup>F-LY2459989 was synthesized by <sup>18</sup>F displacement of a nitro group or an iodonium ylide. PET scans in rhesus monkeys were obtained on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the ligand. Metabolite-corrected arterial activity curves were measured and used as input functions in the analysis of brain time-activity curves and the calculation of binding parameters. <b>Results:</b> With the iodonium ylide precursor, <sup>18</sup>F-LY2459989 was prepared at high radiochemical yield (36% ± 7% [mean ± SD]), radiochemical purity (>99%), and mean molar activity (1,175 GBq/μmol; <i>n</i> = 6). In monkeys, <sup>18</sup>F-LY2459989 was metabolized at a moderate rate, with a parent fraction of approximately 35% at 30 min after injection. Fast and reversible kinetics were observed, with a regional peak uptake time of less than 20 min. Pretreatment with the selective KOR antagonist LY2456302 (0.1 mg/kg) decreased the activity level in regions with high levels of binding to that in the cerebellum, thus demonstrating the binding specificity and selectivity of <sup>18</sup>F-LY2459989 in vivo. Regional time-activity curves were well fitted by the multilinear analysis 1 kinetic model to derive reliable estimates of regional distribution volumes. With the cerebellum as the reference region, regional binding potentials were calculated and ranked as follows: cingulate cortex > insula > caudate/putamen > frontal cortex > temporal cortex > thalamus, consistent with the reported KOR distribution in the monkey brain. <b>Conclusion:</b> The evaluation of <sup>18</sup>F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals. A side-by-side comparison of <sup>18</sup>F-LY2459989 and <sup>11</sup>C-LY2459989 indicated similar kinetic and binding profiles for the 2 radiotracers. Taken together, the results indicated that <sup>18</sup>F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KOR in vivo.
Medical subject headings
- Benzamides
- Fluorine Radioisotopes
- Positron-Emission Tomography
- Pyridines
- Receptors, Opioid, kappa